Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 13  |  Issue : 4  |  Page : 625-630

Efficacy comparison of radiofrequency ablation and hepatic resection for hepatocellular carcinoma: A meta-analysis


1 Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, China
2 Department of Breast Surgery, The Second Hospital of Jilin University, Changchun 130041, China
3 Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, China
4 Department of Colorectal Surgery, The Second Hospital of Jilin University, Changchun 130041, China
5 Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033; Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, China

Correspondence Address:
Tao Jiang
Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033; Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_406_17

Rights and Permissions

Objectives: The objective of this study is to compare the therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection (HR) for the treatment of hepatocellular carcinoma (HCC). Materials and Methods: A literature search was performed for comparative studies reporting outcomes of both RFA and HR for HCC. Pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. Results: A total of 4812 patients with HCC were included, with 2419 in the RFA group and 2393 in the HR group. The 3- and 5-year overall survival rates in the HR group were significantly higher than those in the RFA group (OR: 0.68, 95% CI: 0.58–0.79, P < 0.00001; OR: 0.57, 95% CI: 0.50–0.65, P < 0.00001, respectively). 1-, 3-, 5-year disease-free survival and correspond recurrence-free survival rates were all better in HR group. Conclusion: RFA gets promising clinical outcomes for HCC treatments but is not yet comparable to surgery. HR is still the first-line treatment for HCC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1929    
    Printed25    
    Emailed0    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal